Literature DB >> 456409

A pharmacokinetic study of neostigmine in man using gas chromatography-mass spectrometry.

S M Aquilonius, S A Eckernäs, P Hartvig, J Hultman, B Lindström, P O Osterman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 456409     DOI： 10.1007/bf00558442

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  5 in total

1.  The pharmacokinetics of pyridostigmine.

Authors:  S L Cohan; J L Pohlmann; J Mikszewski; D S O'Doherty
Journal:  Neurology       Date:  1976-06       Impact factor: 9.910

2.  Fate of emepronium in man in relation to its pharmacological effects.

Authors:  A Sundwall; J Vessman; B Strindberg
Journal:  Eur J Clin Pharmacol       Date:  1973-10       Impact factor: 2.953

3.  The effect of chronic pyridostigmine administration on pyridostigmine-14C metabolism in myasthenia gravis.

Authors:  P Kornfeld; R L Wolf; A J Samuels; K E Osserman
Journal:  Neurology       Date:  1971-05       Impact factor: 9.910

4.  Metabolism of 14C-labeled pyridostigmine in myasthenia gravis. Evidence for multiple metabolites.

Authors:  P Kornfeld; A J Samuels; R L Wolf; K E Osserman
Journal:  Neurology       Date:  1970-07       Impact factor: 9.910

5.  A quantitative gas-liquid chromatographic method for the determination of neostigmine and pyridostigmine in human plasma.

Authors:  K Chan; N E Williams; J D Baty; T N Calvey
Journal:  J Chromatogr       Date:  1976-05-26
  5 in total
  9 in total

1.  Pharmacodynamic analysis of contractile potentiation by cholinesterase inhibitors in rats.

Authors:  K Yamamoto; Y Sawada; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1996-08

Review 2.  Clinical pharmacokinetics of cholinesterase inhibitors.

Authors:  S M Aquilonius; P Hartvig
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 3.  Pharmacokinetics in intravenous anaesthetic practice.

Authors:  P Duvaldestin
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

4.  Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis.

Authors:  S M Aquilonius; S A Eckernäs; P Hartvig; B Lindström; P O Osterman; E Stålberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-10       Impact factor: 10.154

Review 5.  First-pass elimination. Basic concepts and clinical consequences.

Authors:  S M Pond; T N Tozer
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

6.  Pharmacokinetics and oral bioavailability of pyridostigmine in man.

Authors:  S M Aquilonius; S A Eckernäs; P Hartvig; B Lindström; P O Osterman
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

7.  Pharmacokinetic studies of ambenonium chloride in patients with myasthenia gravis.

Authors:  C Tharasse-Bloch; C Chabenat; P Boucly; J Marchand; D Elkharrat; C Boucly-Goester; P Gajdos
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Oct-Dec       Impact factor: 2.441

8.  Arginylation regulates purine nucleotide biosynthesis by enhancing the activity of phosphoribosyl pyrophosphate synthase.

Authors:  Fangliang Zhang; Devang M Patel; Kristen Colavita; Irina Rodionova; Brian Buckley; David A Scott; Akhilesh Kumar; Svetlana A Shabalina; Sougata Saha; Mikhail Chernov; Andrei L Osterman; Anna Kashina
Journal:  Nat Commun       Date:  2015-07-15       Impact factor: 14.919

Review 9.  Pyridostigmine in Pediatric Intestinal Pseudo-obstruction: Case Report of a 2-year Old Girl and Literature Review.

Authors:  Giovanni Di Nardo; Federica Viscogliosi; Francesco Esposito; Vincenzo Stanghellini; Maria Pia Villa; Pasquale Parisi; Alessia Morlando; Girolamo Caló; Roberto De Giorgio
Journal:  J Neurogastroenterol Motil       Date:  2019-10-30       Impact factor: 4.924
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.